NYSE:ENFN Enfusion (ENFN) Stock Price, News & Analysis → Dems have chosen Biden replacement? (From Paradigm Press) (Ad) Free ENFN Stock Alerts $9.77 +0.04 (+0.41%) (As of 05/8/2024 ET) Add Compare Share Share Today's Range$9.60▼$9.8050-Day Range$8.18▼$9.7752-Week Range$7.37▼$11.56Volume280,145 shsAverage Volume374,299 shsMarket Capitalization$1.25 billionP/E Ratio122.14Dividend YieldN/APrice Target$9.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Enfusion alerts: Email Address Enfusion MarketRank™ Stock AnalysisAnalyst RatingReduce1.67 Rating ScoreUpside/Downside4.5% Downside$9.33 Price TargetShort InterestHealthy4.66% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.04Based on 3 Articles This WeekInsider TradingSelling Shares$1,179 Sold Last QuarterProj. Earnings Growth142.86%From $0.07 to $0.17 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.37 out of 5 starsComputer And Technology Sector362nd out of 592 stocksPrepackaged Software Industry135th out of 201 stocks 0.8 Analyst's Opinion Consensus RatingEnfusion has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on 1 buy rating, 2 hold ratings, and 3 sell ratings.Amount of Analyst CoverageEnfusion has only been the subject of 2 research reports in the past 90 days.Read more about Enfusion's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.66% of the float of Enfusion has been sold short.Short Interest Ratio / Days to CoverEnfusion has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Enfusion has recently decreased by 3.98%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldEnfusion does not currently pay a dividend.Dividend GrowthEnfusion does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ENFN. Previous Next 2.8 News and Social Media Coverage News SentimentEnfusion has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Computer and Technology companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Enfusion this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for ENFN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enfusion insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,179.00 in company stock.Percentage Held by Insiders39.18% of the stock of Enfusion is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions81.05% of the stock of Enfusion is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Enfusion's insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Enfusion are expected to grow by 142.86% in the coming year, from $0.07 to $0.17 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enfusion is 122.14, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 141.07.Price to Earnings Ratio vs. SectorThe P/E ratio of Enfusion is 122.14, which means that it is trading at a less expensive P/E ratio than the Computer and Technology sector average P/E ratio of about 264.15.Price to Earnings Growth RatioEnfusion has a PEG Ratio of 2.79. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioEnfusion has a P/B Ratio of 16.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Enfusion's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Enfusion Stock (NYSE:ENFN)Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. It also offers Accounting/General Ledger System, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion Analytics System, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion, Inc. was founded in 1997 and is headquartered in Chicago, Illinois.Read More ENFN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENFN Stock News HeadlinesMay 7, 2024 | finance.yahoo.comHas Enfusion, Inc.'s (NYSE:ENFN) Impressive Stock Performance Got Anything to Do With Its Fundamentals?May 7, 2024 | americanbankingnews.comEnfusion, Inc. (NYSE:ENFN) Given Consensus Rating of "Reduce" by BrokeragesMay 9, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.May 2, 2024 | americanbankingnews.comEnfusion (ENFN) to Release Earnings on ThursdayApril 18, 2024 | businesswire.comEnfusion Announces Date of First Quarter 2024 ResultsApril 17, 2024 | morningstar.comEnfusion Inc Class AApril 12, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Enfusion, Inc. - ENFNApril 4, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Enfusion, Inc. - ENFNMay 9, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.April 4, 2024 | msn.comThe 3 Most Undervalued Under-$10 Stocks to Buy in April 2024April 2, 2024 | finance.yahoo.comWill Enfusion (ENFN) Grow Revenue And Expand Margins In The Future?April 2, 2024 | businesswire.comConnexPay Appoints Ben Peters as Chief Executive OfficerMarch 27, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Enfusion, Inc. - ENFNMarch 22, 2024 | markets.businessinsider.comEnfusion’s Growth Strategy Met with Sell Rating Amid Market and Strategic ChallengesMarch 21, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Technology Stocks: GoDaddy (GDDY) and Enfusion (ENFN)March 20, 2024 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on Enfusion (ENFN)March 19, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Enfusion, Inc. - ENFNMarch 15, 2024 | markets.businessinsider.comWall Street Favorites: 3 Under-$10 Stocks with Strong Buy Ratings for March 2024March 14, 2024 | seekingalpha.comEnfusion, Inc. (ENFN) Q4 2023 Earnings Call TranscriptMarch 14, 2024 | finance.yahoo.comEnfusion, Inc. (NYSE:ENFN) Q4 2023 Earnings Call TranscriptMarch 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Technology Companies: Copperleaf Tech (OtherCPLFF), Rackspace Technology (RXT) and Enfusion (ENFN)March 12, 2024 | markets.businessinsider.comWilliam Blair Reaffirms Their Buy Rating on Enfusion (ENFN)March 12, 2024 | msn.comEnfusion reports mixed Q4 results; initiates FY24 outlookMarch 12, 2024 | finance.yahoo.comEnfusion Announces Fourth Quarter 2023 Results and Full Year 2023 ResultsMarch 11, 2024 | benzinga.comEarnings Outlook For EnfusionMarch 6, 2024 | benzinga.comMajor Purchase Alert: Oleg Movchan Invests $120K In Enfusion StockFebruary 29, 2024 | msn.comGoldman Sachs Downgrades Enfusion (ENFN)See More Headlines Receive ENFN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enfusion and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/12/2024Today5/08/2024Next Earnings (Confirmed)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorComputer and Technology Industry Prepackaged software Sub-IndustryN/A Current SymbolNYSE:ENFN CUSIPN/A CIK1868912 Webwww.enfusion.com Phone312-253-9800FaxN/AEmployees1,102Year FoundedN/APrice Target and Rating Average Stock Price Target$9.33 High Stock Price Target$11.00 Low Stock Price Target$8.00 Potential Upside/Downside-4.6%Consensus RatingReduce Rating Score (0-4)1.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)$0.08 Trailing P/E Ratio122.27 Forward P/E Ratio139.71 P/E Growth2.79Net Income$6.03 million Net Margins3.45% Pretax Margin6.58% Return on Equity10.30% Return on Assets7.78% Debt Debt-to-Equity RatioN/A Current Ratio3.44 Quick Ratio3.44 Sales & Book Value Annual Sales$174.54 million Price / Sales7.18 Cash Flow$0.15 per share Price / Cash Flow66.40 Book Value$0.61 per share Price / Book16.03Miscellaneous Outstanding Shares128,070,000Free Float77,892,000Market Cap$1.25 billion OptionableOptionable Beta0.97 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Oleg Movchan (Age 49)CEO & Director Comp: $876.34kMr. Bradley Herring (Age 53)Chief Financial Officer Comp: $267.05kMs. Bronwen Bastone (Age 51)Chief People Officer Comp: $566.25kMr. Stephen MalherbeManaging PartnerMs. Valeria Gutowski (Age 42)Chief Accounting Officer Mr. Daniel Groman (Age 35)Chief Technology Officer Mr. Ignatius Tochukwu NjokuHead of Investor RelationsMr. Joseph DefeoGlobal Head of Managed Services ProductionMr. Jeff YoungHead of ImplementationMr. Robert TaylorHead of Client SupportMore ExecutivesKey CompetitorsPDF SolutionsNASDAQ:PDFSOperaNASDAQ:OPRACouchbaseNASDAQ:BASEFastlyNYSE:FSLYDoceboNASDAQ:DCBOView All CompetitorsInsiders & InstitutionsBleakley Financial Group LLCBought 19,054 shares on 5/8/2024Ownership: 0.015%Swiss National BankBought 11,600 shares on 5/7/2024Ownership: 0.054%Susquehanna Fundamental Investments LLCBought 13,214 shares on 5/7/2024Ownership: 0.010%Allspring Global Investments Holdings LLCBought 4,772 shares on 4/30/2024Ownership: 0.004%Principal Financial Group Inc.Bought 48,913 shares on 4/29/2024Ownership: 0.038%View All Insider TransactionsView All Institutional Transactions ENFN Stock Analysis - Frequently Asked Questions Should I buy or sell Enfusion stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enfusion in the last year. There are currently 3 sell ratings, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" ENFN shares. View ENFN analyst ratings or view top-rated stocks. What is Enfusion's stock price target for 2024? 6 equities research analysts have issued 12 month price targets for Enfusion's shares. Their ENFN share price targets range from $8.00 to $11.00. On average, they expect the company's share price to reach $9.33 in the next twelve months. This suggests that the stock has a possible downside of 4.5%. View analysts price targets for ENFN or view top-rated stocks among Wall Street analysts. How have ENFN shares performed in 2024? Enfusion's stock was trading at $9.70 at the beginning of 2024. Since then, ENFN stock has increased by 0.7% and is now trading at $9.77. View the best growth stocks for 2024 here. Are investors shorting Enfusion? Enfusion saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 2,260,000 shares, a decline of 25.2% from the March 15th total of 3,020,000 shares. Based on an average trading volume of 409,100 shares, the short-interest ratio is currently 5.5 days. Currently, 4.9% of the shares of the stock are short sold. View Enfusion's Short Interest. When is Enfusion's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ENFN earnings forecast. How can I listen to Enfusion's earnings call? Enfusion will be holding an earnings conference call on Thursday, May 9th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link. How were Enfusion's earnings last quarter? Enfusion, Inc. (NYSE:ENFN) issued its earnings results on Tuesday, March, 12th. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.03 by $0.02. The firm had revenue of $46.49 million for the quarter, compared to analyst estimates of $45.56 million. Enfusion had a net margin of 3.45% and a trailing twelve-month return on equity of 10.30%. What guidance has Enfusion issued on next quarter's earnings? Enfusion issued an update on its FY 2024 earnings guidance on Tuesday, March, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $200.0 million-$210.0 million, compared to the consensus revenue estimate of $202.3 million. When did Enfusion IPO? Enfusion (ENFN) raised $300 million in an initial public offering (IPO) on Thursday, October 21st 2021. The company issued 18,750,000 shares at a price of $15.00-$17.00 per share. Who are Enfusion's major shareholders? Enfusion's stock is owned by a variety of institutional and retail investors. Top institutional investors include Wasatch Advisors LP (0.62%), Swiss National Bank (0.05%), Principal Financial Group Inc. (0.04%), Bleakley Financial Group LLC (0.01%), Simplicity Wealth LLC (0.01%) and Susquehanna Fundamental Investments LLC (0.01%). Insiders that own company stock include Bradley Herring, Bronwen Bastone, Dan Groman, Deirdre Somers, Hillhouse Investment Managemen, Matthew Campobasso, Oleg Movchan, Roy Luo, Stephen Malherbe, Tarek Hammoud and Valeria Gutowski. View institutional ownership trends. How do I buy shares of Enfusion? Shares of ENFN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:ENFN) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressObama’s Forever Term [exposed]Porter & CompanyThe A.I. story nobody is telling you (Read ASAP)TradeSmithExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill Publishing348 million Americans lives to END as we know it?The Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enfusion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.